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2108Gluten Challenge Induces Skin and Small
Bowel Relapse in Long-Term Gluten-Free
DieteTreated Dermatitis Herpetiformis
Eriika Mansikka1,2, Kaisa Hervonen1,2, Katri Kaukinen2,3, Tuire Ilus4, Pia Oksanen4,5, Katri Lindfors2,
Kaija Laurila2, Minna Hietikko2, Juha Taavela2,6, Juha Jernman7, Pa¨ivi Saavalainen8,9, Timo Reunala1,2
and Teea Salmi1,2Dermatitis herpetiformis (DH) is an extraintestinal manifestation of celiac disease causing an itchy, blistering
rash. Granular IgA deposits in the skin are pathognomonic for DH, and the treatment of choice is a lifelong
gluten-free diet (GFD). Preliminary evidence suggests that there are patients with DH who redevelop gluten
tolerance after adherence to a GFD treatment. To evaluate this, we performed a 12-month gluten challenge
with skin and small-bowel mucosal biopsy samples in 19 patients with DH who had adhered to a GFD for a
mean of 23 years. Prechallenge biopsy was negative for skin IgA and transglutaminase 3 deposits in 16 patients
(84%) and indicated normal villous height-to-crypt depth ratios in the small bowel mucosa in all 19 patients.
The gluten challenge caused a relapse of the rash in 15 patients (79%) in a mean of 5.6 months; of these 15
patients, 13 had skin IgA and transglutaminase 3 deposits, and 12 had small-bowel villous atrophy. In addition,
three patients without rash or immune deposits in the skin developed villous atrophy, whereas one patient
persisted without any signs of relapse. In conclusion, 95% of the patients with DH were unable to tolerate
gluten even after long-term adherence to a GFD. Therefore, lifelong GFD treatment remains justified in all
patients with DH.
Journal of Investigative Dermatology (2019) 139, 2108e2114; doi:10.1016/j.jid.2019.03.1150INTRODUCTION
Dermatitis herpetiformis (DH) is an extraintestinal manifesta-
tion of celiac disease presenting with an itchy and blistering
rash, mainly on the elbows, knees, and buttocks (Bolotin and
Petronic-Rosic, 2011; Collin et al., 2017). The diagnosis of DH
is confirmed with direct immunofluorescence examination
showing granular IgA deposits in the papillary dermis of per-
ilesional skin (Zone et al., 1996). Marked gastrointestinal
symptoms are rare in DH, although approximately 75% of
patients develop villous atrophy in the small bowel mucosa
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an open access artchanges in the villous structures, intestinal celiac-type
inflammation with increased densities of intraepithelial lym-
phocytes (IELs)—in particular gdþ IELs (Savilahti et al.,
1992)—is evident. Parallel to celiac disease, trans-
glutaminase 2 (TG2)etargeted autoantibodies are frequently
observed in the serum and small-bowel mucosa in untreated
DH and are known to respond to a gluten-free diet (GFD)
(Dieterich et al., 1999; Salmi et al., 2014). However, in DH,
the antigen for deposited cutaneous IgA is epidermal trans-
glutaminase (e.g., transglutaminase 3 [TG3]), another member
of the transglutaminase family along with TG2, and IgA-class
TG3 antibodies (Abs) are often observed in the serum of pa-
tients with DH (Hull et al., 2008; Sa´rdy et al., 2002).
In DH, the treatment of choice is a GFD, which treats both
the rash and small-bowel villous atrophy (Fry et al., 1973).
However, adherence to the diet must be strict; and it has been
observed that the rash typically disappears after a mean
duration of 2 years (Garioch et al., 1994; Reunala et al.,
1977), but IgA and TG3 deposits in the skin are known to
persist much longer (Hietikko et al., 2018). It is generally
accepted that in DH and celiac disease, adherence to GFD
treatment should be lifelong (Caproni et al., 2009;
Ludvigsson et al., 2014). There are, however, a few studies
that show that up to 18% of patients with DH seem to acquire
a tolerance to gluten during the GFD and do not relapse upon
the reintroduction of gluten (Bardella et al., 2003; Garioch
et al., 1994; Leonard et al., 1983; Paek et al., 2011). Like-
wise, there are sporadic reports demonstrating the develop-
ment of gluten tolerance during a GFD in patients with celiac
disease (Hopman et al., 2008; Matysiak-Budnik et al., 2007).s. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology. This is
icle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1. Gluten Challenge Outcome in 19 Patients with Dermatitis Herpetiformis
Patient/Sex/Age
Duration of GFD Before
Challenge, Y
Challenge Outcome
Challenge
Duration, Mo
Skin IgA and TG3
Deposits Pre/
Postchallenge
Serum TG3
Abs7 Pre/
PostchallengeRash
Villous
Atrophy2
Serum
TG2-Targeted
Abs4
1/M/49 5 þ þ e 1 þ/þ6 e/e
2/M/61 5 þ e e 2 þ/þ6 e/e
3/M/60 24 þ þ3 þ 3 e/þ e/þ
4/M/41 20 þ þ þ 3 e/þ e/þ
5/M/65 24 þ þ3 þ 3 e/þ e/þ
6/F/56 31 þ þ3 þ 3 e/e e/þ
7/M/47 14 þ þ3 þ 3 e/þ e/þ
8/M/72 15 þ þ3 þ 4 e/þ þ/þ6
9/M/51 8 þ þ3 þ 4 e/e e/þ
10/F/55 40 þ þ e 6 e/þ e/þ
11/F/68 33 þ þ3 þ 9 e/þ e/þ
12/F/59 34 þ e3 þ 9 e/þ e/e
13/M/58 18 þ þ þ 10 e/þ e/þ
14/M/66 34 þ þ e 12 e/þ e/e
15/F/71 341 þ e e 12 þ/þ e/þ
16/M/56 22 e þ3 þ5 4 e/e þ/þ6
17/F/37 9 e þ3 þ5 4 e/e e/e
18/M/68 221 e þ e 12 e/e e/e
19/M/58 361 e e e 12 e/e e/e
Mean Age at
Prechallenge,
Y (Range)
Mean Duration
of GFD, Y (Range)
Rash, n
(%)
Villous
Atrophy,
n (%)
Serum TG2-
Targeted Abs,
Mean Duration
(Range)
Negative to
Positive, n (%)
Negative to
Positive, n (%)
n (%)
58 (37e72) 23 (5e40) 15 (79) 15 (79) 12 (63) 6.1 (1e12) 10 (53) 10 (53)
Abbreviations: Ab, antibody; F, female; GFD, gluten-free diet; M, male; Mo, month; TG, transglutaminase; Y, year.
1Dietary lapses 1e5 times per month.
2Villous height-to-crypt depth ratio < 2.0.
3TG2-specific IgA deposits in the small bowel mucosa.
4Serum TG2 antibodies  3.0 AU/ml and endomysial antibody titer 1:5.
5Challenge discontinued because of appearance of serum TG2-targeted antibodies.
6At postchallenge, deposits more intense or antibody levels more increased.
7TG3 antibodies > 30 AU/ml.
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Gluten Challenge in Dermatitis HerpetiformisThe aim of this study was to investigate in detail whether
gluten tolerance may exist in patients with DH after long-
term adherence to a GFD. The study specifically focused on
examining the skin TG3 and IgA immune response during
gluten reintroduction in treated subjects with DH. To address
these issues, a gluten challenge of up to 12 months was
performed in volunteering patients with DH in remission, and
the reappearance of the rash, skin IgA and TG3 deposits,
serum TG2- and TG3-targeted Abs, and small bowel mucosal
deterioration were examined.
RESULTS
Of the 19 patients with DH who volunteered for this study, 13
were male and 6 were female, and their mean age was 58
years (see Table 1). At the prechallenge examination, none of
the 19 patients with DH exhibited a rash, and 16 patients
(84%) did not have IgA or TG3 deposits in the skin. Serum
TG2-targeted Abs (TG2 and endomysial Abs [EmAs])
were negative in all patients, and two had slightly elevated
TG3 Ab levels (40 and 41 AU/ml). The small-bowel villous
height-to-crypt depth ratio was normal in all 19 patients (see
Figure 1), and none had TG2-specific IgA deposits in thesmall bowel mucosa. Sixteen patients carried HLA-DQ2
(three homozygous) haplotypes, and three carried HLA-
DQ8 haplotypes.
The gluten challenge led to the reappearance of the DH
rash in 15 patients (79%) in a mean of 5.6 (range, 1e12)
months (see Table 1). At postchallenge, 12 of these patients
evinced small-bowel mucosal villous atrophy, and 10 pa-
tients with a rash had elevated levels of serum TG2-targeted
Abs. However, one patient (patient 12, see Table 1) present-
ing with a rash but a normal villous height-to-crypt depth
ratio at relapse showed a marked increase in the densities of
CD3þ (from 31 cells/mm at prechallenge to 91 cells/mm at
postchallenge) and gdþ (from 10.5 cells/mm at prechallenge
to 38.3 cells/mm at postchallenge) IELs. Two patients who did
not develop a rash during the challenge (patients 16 and 17,
see Table 1) developed high levels of serum IgA-class TG2-
targeted Abs (TG2 Ab levels 100 and 54 AU/ml, EmA titers
1:1000 and 1:500, respectively), because of which the
challenge was discontinued at 4 months. The small bowel
biopsy showed villous atrophy in both patients. In addition,
one patient (patient 18, see Table 1) had no rash or serum
TG2-targeted Abs, but the small bowel biopsy performed atwww.jidonline.org 2109
Figure 1. Villous height-to-crypt
depth ratios in 19 gluten-challenged
patients with dermatitis herpetiformis
at pre- and at postchallenge. Eighteen
patients experienced relapse during
the challenge (pre- , and
postchallenge -). One patient (pre ▵
and postchallenge:) did not relapse
during the challenge. Values above
the dashed line are considered
normal. The two bars on the right-
hand side show mean villous height-
to-crypt depth ratios with 95% CIs at
pre- and postchallenge depicted with
B and C, respectively. CI,
confidence interval.
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211012 months according to the study protocol disclosed villous
atrophy. Thus, a relapse was demonstrated in 18 gluten-
challenged patients (95%) with DH after a mean of 5.8
months (see Table 1). The remaining patient (patient 19, see
Table 1) did not exhibit any skin or gastrointestinal symptoms
during the challenge, and at the final examination at 12
months, the small-bowel villous structures were normal, as
were the densities of CD3þ and gdþ IELs. According to the
dietary diary, the patient’s gluten consumption had been at
least 8 g of gluten per day. After 2 years on a gluten-
containing diet, the patient was still asymptomatic, and the
skin IgA and serum TG2- and TG3-targeted Abs were
negative.
During the gluten challenge, skin IgA became positive in
10 patients with DH, who also developed a rash (see Table 1).
In addition, two of the three patients with the positive skin
IgA findings at prechallenge (patients 1 and 2, see Table 1)
showed more intense fluorescence after the challenge. In
double staining, TG3 was found to colocalize with IgA in all
skin biopsy samples. Two patients (patients 6 and 9, see
Table 1) with the reappearance of the typical DH rash
remained negative for skin IgA and TG3 deposits. In both
patients, the rash was mild and had appeared a few days to 2
weeks before the skin biopsy samples were taken. However,
both had markedly elevated levels (189 AU/ml) of serum TG3
Abs at this time.
When the prechallenge data were compared to the post-
challenge data, significant increase in the median levels of
serum Abs was noted: TG3 Abs from 4 (range, 0e41) to 89
(range, 5e189) AU/ml; TG2 Abs from 0 to 12 (range, 0e100)Journal of Investigative Dermatology (2019), Volume 139AU/ml; and EmA titers from 0 to 1:200 (range, 0e1:4000) (P
< 0.001, in all analyses). In the small-bowel biopsy samples,
the mean villous height-to-crypt depth ratio (see Figure 1)
decreased significantly from 2.8 (standard deviation [SD]
0.59) to 1.2 (SD 0.87) (P < 0.001), whereas the mean den-
sities of CD3þ and gdþ IELs increased significantly from 40
(SD 15) to 74 (SD 29) cells/mm (P < 0.001) and from 10.8
(SD 8.0) to 16.5 (SD 11.3) cells/mm (P ¼ 0.018), respectively.
The Dermatology Life Quality Index mean score increased
significantly (P < 0.001) from 0.11 (SD 0.32) at prechallenge
to 1.58 (SD 2.04) at postchallenge. The total Gastrointestinal
Symptom Rating Scale score showed no significant change
(P ¼ 0.22) with mean scores of 1.66 (SD 0.55) and 1.86 (SD
0.73).
The duration of the GFD before the challenge was shown
to correlate significantly with the relapse time (r ¼ 0.62,
confidence interval ¼ 0.24e0.84; see Figure 2), but age at the
time of the DH diagnosis was found not to correlate with the
relapse time (r ¼ e0.23, confidence interval: e0.62 to 0.25).
DISCUSSION
In this study featuring 19 GFD-treated patients with DH in
remission, a gluten challenge was shown to induce relapse in
95% of the patients. The vast majority (15 of 19 patients,
79%) of the relapsed patients experienced a DH rash, and
most also developed small-bowel mucosal villous atrophy. In
addition, three relapsed patients with no rash exhibited pro-
gression to villous atrophy. The remaining patients, however,
did not manifest any signs of DH or celiac disease during 2
years on a normal gluten-containing diet.
Figure 2. Correlation between the duration of a GFD before the study
(years) and relapse time (months) in 19 gluten-challenged patients with
dermatitis herpetiformis. The 95% CI of the correlation curve is shown in
gray. Patients following a strict GFD before the challenge are marked withB,
and those with a history of dietary lapses are marked withC. One patient not
relapsing during the challenge and with a history of dietary lapses in GFD
before the challenge is marked with:. CI, confidence interval; GFD, gluten-
free diet.
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lenge studies in adults with DH. Parallel results to ours were
found in a study by Leonard et al. (1983): 11 out of 12 pa-
tients (92%) with DH relapsed with a rash, and of these, 7
patients (64%) also developed villous atrophy. Bardella et al.
(2003) reported 31 patients with DH in whom the rash
relapsed within 6 months on a gluten challenge. However,
they also observed seven patients (18% of the study group)
who did not manifest any type of relapse in the skin or small
bowel during the prolonged gluten challenge. It must be
noted that these seven patients had been diagnosed in
childhood, and compliance with a GFD in these nonrelapsed
patients with DH had been only moderate or poor before the
challenge. Therefore, the authors suggested that the ingestion
of small doses of gluten from childhood may induce immune
tolerance (Bardella et al., 2003). Supporting this, the devel-
opment of tolerance to gluten has also been reported in pa-
tients with celiac disease, especially when they have been
diagnosed in childhood and continued to eat a normal
gluten-containing diet (Hopman et al., 2008; Matysiak-
Budnik et al., 2007). In this study, none of the patients had
been diagnosed in childhood, and moreover, our previous
study on GFD-treated children with DH did not find any
patients achieving tolerance to gluten (Hervonen et al.,
2014). Furthermore, three of the patients with DH from thisseries reported dietary lapses when adhering to a GFD, and
two of these patients relapsed. The only patient not relapsing
during the challenge was documented to consume enough
gluten to cause villous atrophy (La¨hdeaho et al., 2011).
However, this patient had been on a GFD for 36 years, which
might cause a delayed DH relapse. Hence, a longer follow-
up than 2 years on a normal gluten-containing diet is
mandatory before a final conclusion of redeveloped gluten
tolerance can be drawn.
In this study, 15 of the gluten-challenged patients with DH
developed villous atrophy, and of these, three patients had no
rash or skin IgA or TG3 deposits. It has been previously
shown that the phenotype of celiac disease can change,
especially from the classical disease to DH (Salmi et al.,
2015), but it is also probable that the patients with DH
without the rash at postchallenge would have developed skin
symptoms if gluten exposure had been prolonged. None-
theless, the results of this study suggest that the gut could be
the initial site of the gluten-induced autoimmune reaction,
that is, celiac disease, and it is only thereafter that the skin
become affected, that is, DH develops (Collin et al., 2017;
Sa´rdy et al., 2002). Nevertheless, we also observed that in
three patients with DH who relapsed with the rash, villous
atrophy had not developed. It is widely recognized that in
celiac disease, small-bowel mucosal changes develop grad-
ually, and villous atrophy is only the end stage of the disease
process and not evident in all affected individuals (Kurppa
et al., 2009). For instance, the presence of small-bowel
mucosal TG2-specific IgA deposits can precede villous at-
rophy in celiac disease (Koskinen et al., 2008), and the de-
posits have been shown to occur also in patients with DH
with normal small bowel mucosa (Salmi et al., 2014). In
agreement with this, one gluten-challenged patient with DH
with no villous atrophy had intestinal TG2-specific IgA
deposits and increased densities of CD3þ and gdþ IELs. In
addition, this patient further showed significant levels of
TG2-targeted Abs in the serum, also suggesting an ongoing
gluten-induced inflammatory response in the small bowel
(Katz et al., 2011; Kumar et al., 2001).
At prechallenge, 16 patients were found not to have IgA and
TG3 deposits in the skin. These deposits are considered
pathognomonic for untreated DH (Donaldson et al., 2007;
Sa´rdy et al., 2002) and are known to resolve slowly during
the GFD treatment (Hietikko et al., 2018). In the previous
challenge studies by Leonard et al. (1983) and Bardella et al.
(2003), 24% and 42% of the patients, respectively, were
found not to have IgA deposits in the skin. In these two studies,
the patients had adhered to GFD treatment for a mean of 8
years, whereas in this study, the mean duration was 23 years,
that is, almost three times longer. This shows that the likeli-
hood of testing negative for skin IgA deposits increases parallel
to the duration of the GFD treatment. It is, however, intriguing
why skin IgA and TG3 deposits persist for several years after
the rash and small-bowel villous atrophy have resolved in
patients on a GFD (Hietikko et al., 2018). The explanation
might be that IgA and TG3 are deposited in the papillary
dermis as immune aggregates in which the TG3 enzyme is
active, resulting in covalent cross-linking of the complex to
dermal structures (Taylor et al., 2015). In contrast to the very
slow disappearance from the skin of a patient on a GFD, thiswww.jidonline.org 2111
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2112study documented a rather rapid reappearance (after 3e12
months) of both IgA and TG3 in ten challenged patients, which
is to our knowledge a previously unreported finding.
This study also examined whether skin IgA and TG3 ag-
gregates reappear simultaneously with the rash. Coincidental
appearance was shown to occur in ten challenged patients.
Unexpectedly, two patients developed the DH rash but
remained skin IgA- and TG3-negative, though they had
markedly elevated TG3 Ab levels in the serum. Skin biopsy
samples were taken from the perilesional skin of both patients
(Donaldson et al., 2007; Zone et al., 1996), making it un-
likely that the results are false negatives. However, there is a
possibility that with a short-term rash, the quantity of IgA and
TG3 in these two patients was so minute that they were not
detectable by the conventional technology that was used.
Skin lesions in DH have been previously produced experi-
mentally by the application of potassium iodide, and these
studies have shown the activation of elastase and urokinase
plasminogen activator enzymes but no alteration in the in-
tensity of IgA deposits (Airola et al., 1997; Reitamo et al.,
1981). Furthermore, Taylor and Zone (2018) showed that
potassium iodine directly activates IgA-bound TG3 in DH
skin and suggested that lesion development is likely depen-
dent on the aberrant activity of the TG3 enzyme.
The major strengths of this study were a well-defined long-
term GFD-treated study group from our prospectively
collected large DH series (Salmi et al., 2011) and the thor-
oughly conducted gluten challenge with regular follow-up
visits and clinical, serological, and small-bowel mucosal bi-
opsy end points. A limitation, however, was the relatively
small number of patients, as was the comparatively short
follow-up time for the nonrelapsed patient with DH.
In conclusion, this 12-month gluten challenge study in
adult patients with DH showed that 95% of the patients had
not achieved tolerance to gluten even after long-term GFD
treatment. The gluten challenge was shown to induce a DH
rash in the majority of the patients, but intriguingly in a few
challenged patients, only small-bowel mucosal deterioration
was documented. Moreover, IgA and TG3 aggregates in the
skin were not disclosed in every patient with a DH rash. At
present, a lifelong adherence to GFD seems justified in all
patients with DH.
MATERIALS AND METHODS
Patients and gluten challenge
A total of 19 patients with DH on a GFD from our prospectively
collected DH series at Tampere University Hospital participated in
the study (see Table 1) (Salmi et al., 2011).
The inclusion criteria were as follows: a diagnosis of DH based on
the typical clinical picture, the presence of granular IgA deposits in
the papillary dermis with direct immunofluorescence examination,
adherence to a GFD for at least 5 years, and absence of skin
symptoms for at least 3 years. The exclusion criteria were as follows:
age > 80 years, severe cardiovascular disease, previous malig-
nancies, and the use of dapsone or immunosuppressive or anti-
coagulation medication other than acetylsalicylic acid. At the time
of the diagnosis of DH, the mean age of the study participants was
35 (range, 19e57) years, and twelve patients (86%) with available
data had small-bowel villous atrophy, and two (14%) had normal
villous architecture in the small bowel mucosa.Journal of Investigative Dermatology (2019), Volume 139Before the gluten challenge, the patients had been on a GFD for a
mean of 23 (range, 5e40) years. Sixteen patients adhered to the diet
strictly, and three reported having 1e5 dietary lapses per month.
The study protocol was approved by the Regional Ethics Com-
mittee of Tampere University Hospital (R16039), and all study par-
ticipants gave their written informed consent.
After the prechallenge investigations, the gluten challenge was
initiated by giving the patients 200 g of commercially available
wheat bread to be consumed daily for 3 days (Anderson et al., 2000).
A follow-up visit was conducted at day 6, and subsequently, the
patients commenced a normal gluten-containing diet with a mini-
mum of 10 g of wheat (i.e., about 1 g of gluten) per day. A follow-up
telephone call was conducted after 3 weeks, and regular follow-up
visits were made every 3 months until the final examination at 12
months. The patients were advised to contact the researchers if they
noticed skin or gastrointestinal symptoms, or if they experienced any
medical problems during the challenge. In such cases, an extra visit
was arranged at the outpatient clinic to consider whether the chal-
lenge should be discontinued.
Clinical and dietary evaluation and questionnaires
At each study visit, patients were examined for the presence of skin,
gastrointestinal, and other celiac diseaseerelated signs. To ensure
the adequate consumption of gluten, a 3-day dietary diary was filled
out by the study participants before every follow-up visit and
analyzed by a dermatologist experienced in GFD treatment.
Dermatology Life Quality Index and Gastrointestinal Symptom
Rating Scale questionnaires assessing the quality of life and the
presence of gastrointestinal symptoms were filled out by the patients
during the study visits. The Dermatology Life Quality Index is used in
dermatological diseases, and it includes six sections: symptoms and
feelings, daily activities, leisure, work and school, personal re-
lationships, and treatment unit. Higher scores indicate decreased
quality of life (Finlay and Khan, 1994). The Gastrointestinal Symp-
tom Rating Scale has been widely used in previous celiac disease
studies (Ludvigsson et al., 2018; Viljamaa et al., 2005), and it in-
cludes five categories: diarrhea, indigestion, constipation, abdom-
inal pain, and reflux. Higher scores indicate more severe symptoms
(Svedlund et al., 1988).
Skin and small-bowel biopsy samples
Skin and small-bowel biopsy samples were obtained at prechallenge
and the end of the gluten challenge to detect findings compatible
with DH and/or celiac disease. The skin biopsy sample was taken
from uninvolved elbow skin or perilesional skin when the rash had
appeared. The samples were fixed in optimal cutting temperature
compound (Tissue-Tek O.C.T. Compound, Sakura Finetek USA,
Torrance, CA), snap-frozen in liquid nitrogen, and stored at e70 C
until examined. To investigate IgA deposits, sections cut from the
samples were stained with TRITC-conjugated goat anti-human IgA
(1:50) (A18786, Life Technologies, Frederick, MD). For the exami-
nation of TG3 deposits, sections were stained with FITC-conjugated
rabbit polyclonal TG3 antibody (1:100) (A030, ZEDIRA GmbH,
Darmstadt, Germany). All sections were further double stained for
IgA and TG3 as previously described (Hietikko et al., 2018).
During gastroscopy, 6e8 forceps biopsy samples were obtained
from the distal part of the duodenum, and at least two samples were
stained with hematoxylin and eosin and investigated with light mi-
croscopy. At least three well-oriented villous crypt units were
measured, and the mean was given as a result. A ratio over 2.0 was
considered normal. The remaining samples were freshly embedded
E Mansikka et al.
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Stainings of CD3þ and gdþ IELs was carried out on 5-mm-thick
frozen sections, and the normal values were <37 cells/mm for CD3þ
and <4.3 cells/mm for gdþ IELs (Ja¨rvinen et al., 2003). Small-bowel
TG2-targeted IgA deposits were studied from unfixed, frozen, 5-mm-
thick small-bowel mucosal sections by direct immunofluorescence
as described by Korponay-Szabo´ et al. (2004).
Serological investigations
Serological investigations were performed at each study visit. The
investigated TG2-targeted Abs were TG2 Abs and EmAs (Korponay-
Szabo´ et al., 2003). TG2 Abs were determined with a commercially
available ELISA kit (Celikey, Phadia, GmbH, Freiburg, Germany) as
previously described (Dieterich et al., 1999), and values  3.0 AU/
ml were considered positive. Serum EmA was measured with an
indirect immunofluorescence method with human umbilical cord as
a substrate, and a titer of 1:5 was regarded as positive (Ladinser
et al., 1994). In cases where TG2-targeted Abs were found to
convert to positive, the challenge was discontinued, and post-
challenge investigations were carried out. TG3 Abs were determined
with a commercially available ELISA kit (Immundiagnostik, Ben-
sheim, Germany) as previously described (Reunala et al., 2015), and
values >30 AU/ml were considered positive. Elevation of serum TG3
Abs alone was not considered a reliable marker of DH or celiac
disease relapse and thus was not considered a sufficient reason for
challenge discontinuation. HLA DQ2 and DQ8 genotypes were
determined using the Olerup SSP DQB1 low-resolution kit (Olerup
SSP AB, Saltsjo¨baden, Sweden/Qiagen Vertriebs GmbH, Vienna,
Austria).
Statistical analysis
Statistical comparisons within-subjects were performed by permu-
tation test or Wilcoxon matched-pairs signed rank test with exact
P-values. Correlations were estimated by Spearman correlation co-
efficient method. The normality of the variables was tested by using
the Shapiro-Wilk W test. Stata 15.0 (StataCorp LP, College Station,
TX) statistical package was used for the analysis.
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